ZTS:NYE-Zoetis Inc. Class A (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 164.6

Change

0.00 (0.00)%

Market Cap

USD 24.45B

Volume

1.80M

Analyst Target

USD 173.36
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Zoetis Inc discovers, develops, manufactures & commercializes animal health medicines & vaccines for livestock & companion animals. Its products include anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceutical products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-28 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
HLN Haleon plc

N/A

USD 44.13B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 42.24B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 13.11B
CTLT Catalent Inc

N/A

USD 11.52B
ELAN Elanco Animal Health

N/A

USD 5.75B
AMRX Amneal Pharmaceuticals, Inc. C..

N/A

USD 3.59B
BHC Bausch Health Companies Inc

N/A

USD 2.75B
CPHI China Pharma Holdings Inc

N/A

USD 3.69M
YCBD cbdMD Inc

N/A

USD 1.96M
PBH Prestige Brand Holdings Inc

N/A

N/A

ETFs Containing ZTS

ZEAT:CA BMO Global Agriculture ET.. 7.98 % 0.00 %

N/A

N/A
PETZ:LSE 7.07 % 0.00 %

N/A

N/A
KATZ:XETRA 7.03 % 0.00 %

N/A

N/A
PETZ:SW 7.03 % 0.00 %

N/A

N/A
C9DF:XETRA Frankfurter UCITS-ETF - M.. 4.10 % 0.00 %

N/A

N/A
CBUF:F iShares V Public Limited .. 3.14 % 0.00 %

N/A

N/A
WHCS:SW iShares MSCI World Health.. 3.08 % 0.00 %

N/A

N/A
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

N/A

N/A
MOO VanEck Agribusiness ETF 0.00 % 0.54 %

N/A

N/A
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

N/A

N/A
FTXH First Trust Nasdaq Pharma.. 0.00 % 0.60 %

N/A

USD 0.01B
IVFGC 0.00 % 0.00 %

N/A

N/A
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

N/A

CAD 0.05B
HWF:CA 0.00 % 0.00 %

N/A

N/A
VLQ:CA 0.00 % 0.40 %

N/A

N/A
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

N/A

N/A
HHL:CA Harvest Healthcare Leader.. 0.00 % 1.15 %

N/A

N/A
PSWU:LSE 0.00 % 0.00 %

N/A

N/A
XMEM:LSE Xtrackers MSCI Emerging M.. 0.00 % 0.00 %

N/A

N/A
PWC:PA 0.00 % 0.00 %

N/A

N/A
6PSH:F 0.00 % 0.00 %

N/A

N/A
6PSH:XETRA 0.00 % 0.00 %

N/A

N/A
EKLD:XETRA BNP Paribas Easy MSCI USA.. 0.00 % 0.00 %

N/A

USD 0.53B
DUAL 0.00 % 0.00 %

N/A

N/A
DIET 0.00 % 0.00 %

N/A

N/A
CBUF:XETRA iShares MSCI World Health.. 0.00 % 0.00 %

N/A

USD 1.13B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.60% 33% F 14% F
Dividend Return 0.88% 17% F 12% F
Total Return -15.73% 33% F 13% F
Trailing 12 Months  
Capital Gain -16.60% 33% F 14% F
Dividend Return 0.88% 17% F 12% F
Total Return -15.73% 33% F 13% F
Trailing 5 Years  
Capital Gain 24.50% 71% C- 63% D
Dividend Return 4.79% 20% F 12% F
Total Return 29.29% 64% D 56% F
Average Annual (5 Year Horizon)  
Capital Gain 7.72% 53% F 59% D-
Dividend Return 8.44% 47% F 54% F
Total Return 0.72% 50% F 19% F
Risk Return Profile  
Volatility (Standard Deviation) 20.63% 80% B- 53% F
Risk Adjusted Return 40.91% 67% D+ 56% F
Market Capitalization 24.45B 100% F 97% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 36.00 44% 23%
Price/Book Ratio 14.21 30% 7%
Price / Cash Flow Ratio 31.61 20% 10%
Price/Free Cash Flow Ratio 20.99 20% 17%
Management Effectiveness  
Return on Equity 47.30% 100% 96%
Return on Invested Capital 20.72% 100% 89%
Return on Assets 14.66% 100% 98%
Debt to Equity Ratio 131.36% 33% 27%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.